AzTrials
AzTrials

Anorexia NervosaNCT06818695

Online Imaginal Exposure Therapy for Eating Disorders Trial

A study testing Imaginal Exposure for Anorexia Nervosa and Treatment as Usual (TAU) in people with Anorexia Nervosa, run by University College, London at 1 site in United Kingdom.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this clinical trial is to learn if an imaginal exposure intervention first conducted by Levinson and colleagues (2020) can produce similar promising results in individuals with anorexia on the waiting list of an NHS eating disorder service. The main question it aims to answer is: 1. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Anorexia Nervosa
What is being tested?
Imaginal Exposure for Anorexia Nervosa and Treatment as Usual (TAU)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
76 participants
Where
1 siteUnited Kingdom
Study dates
Apr 2025to Jun 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients on the North East London Foundation Trust Eating Disorder waiting list.
  • Patients who are over the age of 18 years old.
  • Patients of all genders.
  • Patients who have a primary diagnosis of Anorexia Nervosa.
  • Patients who are willing and able to provide written informed consent.

Who cannot join

  • Patients on the waiting list who are under the age of 18.
  • Females who are pregnant, planning pregnancy or breastfeeding.
  • Patients involved in concurrent research which is likely to interfere with the imaginal exposure intervention.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Amber L Cameron, BA Experimental Psychology contact

+44 7703329648

ucju575@ucl.ac.uk

Lucy Serpell contact

l.serpell@ucl.ac.uk

United Kingdom1 site
  • North East London Foundation Trust Eating Disorder Service

    London, Barking, IG11 7RS

    Lucy Serpell, l.serpell@ucl.ac.uk

    Emilia Severs, emilia.severs@nelft.nhs.uk

Other trials in United Kingdom

About this study

Official title: Efficacy of Online Imaginal Exposure Therapy for Individuals With Anorexia Nervosa

The goal of this clinical trial is to learn if an imaginal exposure intervention first conducted by Levinson and colleagues (2020) can produce similar promising results in individuals with anorexia on the waiting list of an NHS eating disorder service. The main question it aims to answer is:

  1. How effective is Imaginal Exposure Therapy in reducing eating disorder symptoms and increasing weight in patients with AN? The secondary research questions are:
  2. How effective is Imaginal Exposure Therapy in reducing anxiety and fear related outcomes around food and eating?
  3. How effective is Imaginal Exposure Therapy in improving patients' general anxiety and depression symptoms?
Read more

Researchers will compare the results of individuals in the treatment condition to individual's in the control condition to explore the efficacy of the intervention on eating disorder and eating disorder fear symptomology, and body weight.

Participants in the intervention group will receive 4 sessions of online exposure therapy, and participants in the control group will remain on the waiting list with treatment as usual (primarily nurse monitoring).

Read the detailed description

Study design type: The study will have a parallel group design. Approximately half of the participants will be randomised to receive our intervention, IE for AN. The other half will remain on the waitlist for the service and receive treatment as usual (TAU), which includes specialist nurse monitoring, occasional medical reviews, and dietetic support (depending on the individual's particular needs). This study design will allow us to directly assess the efficacy of the IE intervention, as compared to standard waiting list monitoring, on participants' weight and AN symptoms.

Sampling: Potential participants will be identified by the direct care team; any details not obtained through the study questionnaires will be obtained through digital medical records. The researchers will request information where needed through the direct care team. Participants will be recruited through the NELFT ED service post referral triage, while patients are on the waiting list. Participants will be the adults on the waiting list for receiving AN treatment at NELFT.

Procedure: Following informed consent, participation in the trial will last 5 weeks.

Week 1: All participants will, where possible, come to the service in-person to be weighed. All participants will complete a set of psychometric questionnaires during this appointment. The IE group will also complete the Eating Disorder Fear Interview (Levinson et al., 2019), administered in order to identify a fear to target in exposure therapy. If not possible to attend in-person, this primary appointment will be held on Zoom. All baseline appointments will be with a study coordinator.

Week 2: First online imaginal exposure. Week 3: Second online imaginal. Week 4: Third online imaginal exposure. Week 5: Fourth online imaginal exposure and participants will complete the final battery of online questionnaires. They will then come to the service in-person to be weighed again.

Being tested
Imaginal Exposure for Anorexia Nervosa, Treatment as Usual (TAU)
Keywords
Intervention Study, Anorexia Nervosa, Imaginal Exposure, Waiting List Controls, Parallel Group Design
Medical subject headings
Anorexia Nervosa

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Imaginal Exposure for Anorexia NervosaOther

    Imaginal exposure aims to use the power of imagining the fearful situation to heighten anxiety and by not engaging in imaginative restriction or other eating disorder behaviours, the individual, in theory, can habituate to the anxiety until it naturally subsides.

  • Treatment as Usual (TAU)Other

    TAU includes specialist nurse monitoring, occasional medical reviews, and dietetic support (depending on the individual's particular needs)

Study groups in NCT06818695
Study groupRoleWhat they receive
Treatment ArmExperimentalParticipants will receive imaginal exposure for Anorexia Nervosa
Receives: Other: Imaginal Exposure for Anorexia Nervosa
Waitlist ControlActive comparatorParticipants in this arm will remain on the waitlist for the service and receive treatment as usual (TAU), which includes specialist nurse monitoring, occasional medical reviews, and dietetic support (depending on the individual's particular needs).
Receives: Other: Treatment as Usual (TAU)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Eating Disorder Examination Questionnaire

    A 28-item questionnaire aiming to assess the characteristics, range, frequency and severity of behaviours associated with clinical eating disorders such as Anorexia Nervosa, Bulimia Nervosa, Binge Eating Disorder and OSFED. It consists of 4 subscales: Restraint, Eating Concern, Shape Concern and Weight Concern and overall global score. Higher scores are indicative of more severe eating difficulties and the scale is used as an assessment and diagnostic tool.

    Measured: From initial interview till the end of treatment after 5 weeks

  2. Body Mass Index

    BMI is a measure using an individual's tissue mass (weight) and height to determine body mass index, which is categorised into the following: Underweight (under 18.5 kg/m2), Normal Weight (18.5-24.9) Overweight (25-29.9) and Obese (30 or more).

    Measured: From initial session until the end of intervention at 5 weeks

Secondary outcomes (5)
  1. Fear of Food Measure (FOFM)

    Designed by Levinson et al., specifically to assess improvement in Eating Related Anxiety over the course of Imagined Exposure Therapy. It consists of 3 subscales: Anxiety about Eating, Food Avoidance Behaviours, and Feared Concerns.

    Measured: From initial session to the end of the intervention at 5 weeks

  2. Eating Disorder Fears Interview (EFI)

    Designed by Levinson et al., the EFI is a semi-structured interview consisting of 31 items designed to assess common ED fears such as food, weight gain and consequences of weight gain (judgement). This interview can also be used in tandem with Eating Disorder clinical assessment interviews to attain a more in depth understanding of treatment aims and goals.

    Measured: From initial session to the end of intervention at 5 weeks

  3. Eating Disorder Fears Questionnaire (EFQ)

    Designed by Levinson et al., the EFQ is a 30 item self-report measure designed to assess common ED fears such as gaining weight, consequences of weight gain, and eating in public.

    Measured: From initial session to the end of intervention at 5 weeks

  4. Penn State Worry Questionnaire (PSWQ)

    A 16 Item Questionnaire assessing traits of worrying in adults. The scale measures three dimensions of worrying: excessive, generality and uncontrollable.

    Measured: From initial session to end of intervention at 5 weeks.

  5. Beck Depression Inventory II (BDI-II)

    The BDI-II is a 21 item self report inventory measuring severity of depression in adolescents and adults.

    Measured: From the initial session to the end of the intervention at 5 weeks.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Feb 2025
  2. Study startApr 2025 (estimated)
  3. Primary completionApr 2026 (estimated)
  4. Study completionJun 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
76 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06818695
Sponsor's protocol ID
162510
Status last verified
Apr 2025
First submitted
7 Feb 2025
Last updated
6 Apr 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Levinson CA, Christian C, Ram SS, Vanzhula I, Brosof LC, Michelson LP, Williams BM. Eating disorder symptoms and core eating disorder fears decrease during online imaginal exposure therapy for eating disorders. J Affect Disord. 2020 Nov 1;276:585-591. doi: 10.1016/j.jad.2020.07.075. Epub 2020 Jul 21.

    PubMed 32794449

Questions about this trial

What is this clinical trial studying?

A study testing Imaginal Exposure for Anorexia Nervosa and Treatment as Usual (TAU) in people with Anorexia Nervosa, run by University College, London at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 6 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Amber L Cameron, BA Experimental Psychology (+44 7703329648, ucju575@ucl.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Eating Disorder Examination Questionnaire (time frame: From initial interview till the end of treatment after 5 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06818695, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Apr 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in